Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Omvoh shows 63.5% durable disease clearance in ulcerative colitis patients after 4 years of treatment
LLY
$1,222.99
+$25.00 +2.09%

Omvoh shows 63.5% durable disease clearance in ulcerative colitis patients after 4 years of treatment

Company Fundamentals
05 May 2026
PRNewsWire
View Source
Bullish
pluang ai news

New data from Eli Lilly reveal that 63.5% of ulcerative colitis patients treated with Omvoh maintained disease clearance after four years of continuous treatment. Disease clearance means simultaneous symptom relief, and endoscopic and histologic remission, a high clinical standard linked to fewer hospitalizations and surgeries. This is the first IL-23p19 inhibitor to demonstrate such long-term durable remission, potentially changing the disease's long-term course. Eli Lilly is also exploring combination therapies and pediatric trials to further improve outcomes.

More News (LLY)

Law firm probes fairness of AtaiBeckley sale to Eli Lilly amid shareholder concerns over low price.

Law firm probes fairness of AtaiBeckley sale to Eli Lilly amid shareholder concerns over low price.

Wohl & Fruchter LLP is investigating whether the proposed sale of AtaiBeckley to Eli Lilly at $6.75 per share plus a contingent value right (CVR) up to $2.50 is fair to shareholders. The deal price is significantly below Wall Street analysts' targets...

Market News
Bearish
11 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App